IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immuneering Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $236.79M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
53.3%
34M of 65M shares
Institutional holders
112
38 new, 21 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $270.46K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 8,787,052 | 14.50% | 13G (passive) | Sep 30, 2025 |
| Martin D. Hoe | 5,188,755 | 8.83% | 13G (passive) | Sep 30, 2025 |
| Benjamin J. Zeskind | 4,357,807 | 6.60% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 4,356,235 | 6.70% | 13G (passive) | Jun 30, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 3,646,304 | 5.70% | 13G (passive) | Sep 26, 2025 |
| Merrin Investors LLC | 2,770,386 | 9.46% | 13G (passive) amendment | Mar 27, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,704,610 | 15.00% | $48.43M | +6,672 | 0.00% |
| BlackRock, Inc. | 4,374,020 | 6.76% | $21.83M | +2,866,762 | 0.00% |
| Sanofi | 2,708,559 | 4.19% | $13.52M | – | 2.53% |
| Vanguard Capital Management LLC | 2,286,434 | 3.53% | $11.41M | −1,907 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,936,076 | 2.99% | $9.66K | +106,888 | 0.00% |
| Geode Capital Management, LLC | 1,370,750 | 2.12% | $6.84M | +732,806 | 0.00% |
| State Street Corp | 1,001,995 | 1.55% | $5.00M | +733,475 | 0.00% |
| DCF Advisers, LLC | 790,000 | 1.22% | $3.94M | +648,538 | 0.70% |
| Marshall Wace, Llp | 731,897 | 1.13% | $3.65M | −1,264,688 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 601,255 | 0.93% | $3.00M | +200,892 | 0.01% |
| Alethea Capital Management, LLC | 472,935 | 0.73% | $2.36M | +450,000 | 0.98% |
| Summit Financial, LLC | 452,264 | 0.70% | $2.26M | +75,515 | 0.02% |
| UBS Group AG | 448,857 | 0.69% | $2.24M | +72,573 | 0.00% |
| Nuveen, LLC | 438,362 | 0.68% | $2.19M | New | 0.00% |
| Northern Trust Corp | 436,992 | 0.68% | $2.18M | +319,326 | 0.00% |
| Levin Capital Strategies, L.P. | 414,000 | 0.64% | $2.07M | +404,000 | 0.14% |
| Citadel Advisors LLC | 386,411 | 0.60% | $1.93M | −60,867 | 0.00% |
| Vanguard Fiduciary Trust Co | 360,764 | 0.56% | $1.80M | +38,726 | 0.00% |
| Vanguard Portfolio Management LLC | 359,085 | 0.56% | $1.79M | New | 0.00% |
| Gsa Capital Partners Llp | 343,303 | 0.53% | $1.71K | +266,551 | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 112 | 34M | 53.3% | 38 / 35 | 21 / 21 | 9M | 4M |
| Q1 2026 | 95 | 29M | 45.3% | 30 / 27 | 22 / 18 | 8M | 7M |
| Q4 2025 | 86 | 32M | 49.1% | 31 / 27 | 12 / 13 | 10M | 5M |
| Q3 2025 | 68 | 26M | 40.3% | 33 / 24 | 6 / 4 | 23M | 0M |
| Q2 2025 | 39 | 4M | 6.0% | 11 / 8 | 6 / 7 | 1M | 1M |
| Q1 2025 | 35 | 4M | 7.0% | 5 / 9 | 9 / 12 | 1M | 1M |
| Q4 2024 | 42 | 4M | 6.7% | 7 / 12 | 10 / 3 | 0M | 0M |
| Q3 2024 | 38 | 4M | 6.7% | 7 / 8 | 17 / 27 | 1M | 6M |
| Q2 2024 | 59 | 10M | 14.8% | 28 / 10 | 19 / 19 | 4M | 6M |
| Q1 2024 | 51 | 12M | 18.5% | 7 / 15 | 23 / 8 | 1M | 5M |
| Q4 2023 | 52 | 16M | 25.0% | 4 / 18 | 17 / 4 | 0M | 1M |
| Q3 2023 | 52 | 17M | 26.2% | 7 / 24 | 11 / 4 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 2,943,677 | 4.55% | $16.99M | 0.02% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,623,577 | 2.51% | $8.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,364,794 | 2.11% | $6.81M | 0.01% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,095,798 | 1.69% | $6.32M | 0.12% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 906,762 | 1.40% | $4.52M | 0.03% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 828,054 | 1.28% | $4.78M | 0.02% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 719,805 | 1.11% | $4.15M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 612,343 | 0.95% | $3.06M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 584,479 | 0.90% | $2.41M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 496,639 | 0.77% | $2.48M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 387,692 | 0.60% | $1.93M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 387,578 | 0.60% | $1.93M | 0.02% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 330,397 | 0.51% | $1.36M | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 281,673 | 0.44% | $1.63M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 180,332 | 0.28% | $899.86K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Benjamin J. Zeskind | PRESIDENT AND CEO, Director | 3,210,179 | 4.96% | Jun 24, 2026 |
| Andrew Gengos | Chief Financial Officer | 225,000 | 0.35% | Jul 17, 2026 |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | 382,531 | 0.59% | Jun 16, 2026 |
| Leah R. Neufeld | CHIEF PEOPLE OFFICER | 29,598 | 0.05% | Mar 17, 2026 |
| Igor Matushansky | Chief Medical Officer | – | – | Feb 5, 2026 |
| Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | 4,870 | 0.01% | Feb 5, 2026 |
| Mallory Morales | SVP Finance, CAO | 27,533 | 0.04% | Feb 5, 2026 |
| Harold Eugene Brakewood | Chief Business Officer | 11,050 | 0.02% | Feb 5, 2026 |
| Diana Hausman | Director | 5,500 | 0.01% | Jun 11, 2026 |
| Thomas J. Schall | Director | 74,530 | 0.12% | Jun 11, 2026 |
| Laurie Keating | Director | 14,000 | 0.02% | Jun 11, 2026 |
| Robert J. Carpenter | Director | 1,148,839 | 1.78% | Jun 11, 2026 |
| Peter Feinberg | Director | 1,161,064 | 1.79% | Jun 11, 2026 |
| Ann E. Berman | Director | 67,465 | 0.10% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Benjamin J. Zeskind PRESIDENT AND CEO, Director | Jun 23, 2026 | Buy | +2,400 | $4.56 | $10.94K | 2,315,252 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 15, 2026 | Buy | +6,035 | $4.15 | $25.05K | 382,531 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 13, 2026 | Award | +3,628 | $4.29 | $15.56K | 29,598 |
| Harold Eugene Brakewood Chief Business Officer | Jan 16, 2026 | Buy | +5,250 | $4.76 | $24.99K | 11,050 |
| Thomas J. Schall Director | Jan 15, 2026 | Buy | +21,645 | $4.67 | $101.08K | 74,530 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jan 15, 2026 | Buy | +2,298 | $4.57 | $10.50K | 376,496 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Jan 13, 2026 | Buy | +2,626 | $4.15 | $10.90K | 25,970 |
| Peter Feinberg Director | Jan 12, 2026 | Buy | +20,000 | $4.35 | $87.00K | 135,441 |
| Peter Feinberg Director | Oct 3, 2025 | Buy | +7,500 | $6.67 | $50.03K | 156,766 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Oct 1, 2025 | Buy | +800 | $6.38 | $5.10K | 23,344 |
| Mallory Morales Chief Accounting Officer | Oct 1, 2025 | Buy | +300 | $6.39 | $1.92K | 27,533 |
| Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | Oct 1, 2025 | Buy | +1,020 | $6.83 | $6.97K | 4,870 |
| Peter Feinberg Director | Sep 30, 2025 | Buy | +7,500 | $7.03 | $52.73K | 149,266 |
| Peter Feinberg Director | Sep 29, 2025 | Buy | +5,000 | $7.18 | $35.90K | 141,766 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Sep 15, 2025 | Award | +14,880 | $1.43 | $21.28K | 374,198 |
| Mallory Morales Chief Accounting Officer | Sep 15, 2025 | Award | +14,497 | $1.43 | $20.73K | 27,233 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Sep 15, 2025 | Award | +11,815 | $1.43 | $16.90K | 22,544 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Jul 2, 2025 | Buy | +700 | $3.57 | $2.50K | 10,729 |
| Diana Hausman Director | Jul 2, 2025 | Buy | +3,000 | $3.62 | $10.86K | 3,000 |
| Diana Hausman Director | Jul 2, 2025 | Buy | +2,500 | $3.60 | $9.00K | 2,500 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jul 2, 2025 | Buy | +7,015 | $3.53 | $24.76K | 2,312,852 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jul 1, 2025 | Buy | +2,985 | $3.38 | $10.09K | 2,305,837 |
| Thomas J. Schall Director | Jun 27, 2025 | Buy | +9,500 | $3.66 | $34.77K | 52,885 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 23, 2025 | Buy | +6,007 | $2.43 | $14.60K | 359,318 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 20, 2025 | Buy | +7,415 | $2.70 | $20.02K | 353,311 |
| Harold Eugene Brakewood Chief Business Officer | Jun 20, 2025 | Buy | +1,900 | $2.53 | $4.81K | 5,800 |
| Peter Feinberg Director | Jun 18, 2025 | Buy | +25,000 | $2.53 | $63.25K | 136,766 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jun 18, 2025 | Buy | +21,000 | $2.39 | $50.19K | 2,302,852 |
| Thomas J. Schall Director | Jun 17, 2025 | Buy | +40,485 | $2.21 | $89.47K | 43,385 |
| Mallory Morales Chief Accounting Officer | Sep 15, 2024 | Award | +4,458 | $1.62 | $7.22K | 12,736 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −100 | $3.05 | $305 | 3,294,773 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −600 | $3.03 | $1.82K | 3,294,173 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −100 | $3.07 | $307 | 3,295,173 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −300 | $3.07 | $921 | 3,294,873 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −398,600 | $2.90 | $1.16M | 2,895,273 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −10 | $3.01 | $30 | 3,294,163 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −10 | $2.98 | $30 | 3,294,153 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −280 | $2.97 | $832 | 3,293,873 |
| Peter Feinberg Director | Mar 22, 2024 | Buy | +25,000 | $2.55 | $63.75K | 111,766 |
| Thomas J. Schall Director | Mar 22, 2024 | Buy | +2,900 | $2.55 | $7.39K | 2,900 |
| Harold Eugene Brakewood Chief Business Officer | Mar 22, 2024 | Buy | +3,900 | $2.57 | $10.02K | 3,900 |
| Mallory Morales Chief Accounting Officer | Mar 22, 2024 | Buy | +393 | $2.55 | $1.00K | 8,278 |
| Mallory Morales Chief Accounting Officer | Mar 21, 2024 | Buy | +1,107 | $2.72 | $3.01K | 7,885 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Mar 20, 2024 | Buy | +7,000 | $2.86 | $20.02K | 345,896 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 20, 2024 | Buy | +3,818 | $2.88 | $11.00K | 10,029 |
| Peter Feinberg Director | Mar 19, 2024 | Buy | +25,000 | $2.56 | $64.00K | 86,766 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Mar 19, 2024 | Buy | +20,000 | $2.77 | $55.40K | 2,281,852 |
| Peter Feinberg Director | Mar 18, 2024 | Buy | +45,024 | $2.31 | $104.01K | 56,790 |
| Peter Feinberg Director | Mar 18, 2024 | Buy | +4,976 | $3.05 | $15.18K | 61,766 |
| Ann E. Berman Director | Mar 18, 2024 | Buy | +57,965 | $2.13 | $123.47K | 67,465 |
| Mallory Morales Chief Accounting Officer | Mar 15, 2024 | Award | +4,344 | $1.62 | $7.04K | 6,778 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Mar 15, 2024 | Award | +6,211 | $1.62 | $10.06K | 338,896 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 15, 2024 | Award | +6,211 | $1.62 | $10.06K | 6,211 |
| Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | Mar 15, 2024 | Award | +1,448 | $1.62 | $2.35K | 3,850 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 15, 2024 | Sale | −400,000 | $2.14 | $856.00K | 3,295,273 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −345,266 | $3.24 | $1.12M | 3,859,098 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −98,570 | $4.25 | $418.92K | 3,760,528 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −54,215 | $5.37 | $291.13K | 3,706,313 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −11,040 | $5.97 | $65.91K | 3,695,273 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Dec 22, 2022 | Option exercise | +2,500 | $3.01 | $7.52K | 2,261,852 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ann E. Berman Director | Sep 23, 2025 | 14,000 | $136.08K | Sep 23, 2025 | Open Market Purchase |